Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Andreas Neophytides"'
A previously healthy 72-year-old man presented with 1 year of progressive ataxia and slurred speech. There was no notable family history and no history of alcohol abuse or neurotropic drug use. Examination showed bilateral hypometric saccades, a 2–
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8cfcecd45169ea06bdb647206d6fb0a
https://europepmc.org/articles/PMC5648197/
https://europepmc.org/articles/PMC5648197/
Autor:
Greg Baumann, Edith Miller, Andreas Neophytides, Abraham Lieberman, Linda Chin, Govindan Gopinathan
Publikováno v:
European Neurology. 30:75-78
Sinemet-controlled release (CR4) consisting of 50 mg carbidopa/200 mg levodopa was compared with Sinemet 25/100 in 24 Parkinson's disease (PD) patients during a 16-week double-blind cross-over study. The mean age of the patients was 66.2 years, their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f419c3584b2de5287b3c3e5e52c002e9
https://doi.org/10.1159/000117314
https://doi.org/10.1159/000117314
Publikováno v:
Neurosurgery. 40(4)
Objective To evaluate the efficacy of embolization for spinal dural arteriovenous fistulae (SDAVF). Methods We reviewed 49 cases of SDAVF treated by embolization. An acrylic material was used in all except two cases. Variable stiffness microcatheters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afb460ac01af362b170d2ee79ef4e489
https://pubmed.ncbi.nlm.nih.gov/9092840
https://pubmed.ncbi.nlm.nih.gov/9092840
Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 46:905-910
Cerebrospinal fluid levels of homovanillic acid (HVA) in unmedicated patients with Parkinson's disease were 45% of levels in control subjects. Levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and platelet monoamine oxidase activity (MAO) did not diff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::100e7b2020b4b66681261f35b0f63f71
https://doi.org/10.1136/jnnp.46.10.905
https://doi.org/10.1136/jnnp.46.10.905
Autor:
Paul F. Teychenne, Adrian Williams, Andreas Neophytides, Charles Plotkin, John G. Nutt, Donald B. Calne
Publikováno v:
The Lancet. 311:735-738
92 patients with parkinsonism have been treated with bromocriptine for up to 30 months. 48 continue to receive bromocriptine with benefit; of these, 35 take bromocriptine (mean dose 53 mg daily) in combination with levodopa and 13 take bromocriptine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81f966a885ed906460e4143ea5e00bda
https://doi.org/10.1016/s0140-6736(78)90856-5
https://doi.org/10.1016/s0140-6736(78)90856-5
Autor:
Morton Leibowitz, Andreas Neophytides, Russell W. Walker, Virginia Pact, Abraham Lieberman, Govindan Gopinathan, Menek Goldstein
Publikováno v:
Clinical Pharmacology and Therapeutics. 32:70-75
Pergolide, a semisynthetic ergoline and a potent long-acting adenylcyclase-linked dopamine agonist, was given to 40 patients with advanced Parkinson s disease whose response to levodopa had diminished considerably. The group included 31 patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1802162943aa1c7a983051d35c88573d
https://doi.org/10.1038/clpt.1982.128
https://doi.org/10.1038/clpt.1982.128
Autor:
Russell W. Walker, Abraham Lieberman, Govindan Gopinathan, Andreas Neophytides, Morton Leibowitz, Emil Hiesiger
Publikováno v:
Annals of Neurology. 13:44-47
Lisuride was compared with bromocriptine in 25 parkinsonian patients in whom the response to levodopa had diminished; 19 had "wearing off," "on-off" phenomena, or both. At the time bromocriptine was added to levodopa, the mean age of the patients was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1bf4ce963e4c06a45d4ce1095ca126e
https://doi.org/10.1002/ana.410130110
https://doi.org/10.1002/ana.410130110
Autor:
Hassan Hassouri, Andreas Neophytides, Abraham Lieberman, Govindan Gopinathan, Menek Goldstein
Publikováno v:
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 11:233-237
Experience with bromocriptine in 106 patients treated over nine years was reviewed. Most of the patients were already being treated with levodopa (combined with a peripheral decarbosylase inhibitor). These patients, after having initially achieved a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01c559461d24af72a61aed22b2e03770
https://doi.org/10.1017/s0317167100046473
https://doi.org/10.1017/s0317167100046473
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 47:1348-1351
The alteration in circulating levels of PRL, GH, TSH, and cortisol was studied after the oral administration of muscimol (3-hydroxy-5-aminomethylisoxazole) to human subjects with Huntington's disease (n = 4) and chronic schizophrenia (n = 5). PRL lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ea8c97d22065df6cb6b3174c498303d
https://doi.org/10.1210/jcem-47-6-1348
https://doi.org/10.1210/jcem-47-6-1348
Publikováno v:
Clinical Neuropharmacology. 9:S9-S21
In the past decade, dopamine agonists have emerged as important treatment options for patients with Parkinson's disease. Originally, dopamine agonists were used only in patients with advanced disease in whom the response to levodopa had decreased (le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e0a229a23fa30a90a80416bde1b8135
https://doi.org/10.1097/00002826-198612030-00003
https://doi.org/10.1097/00002826-198612030-00003